NASDAQ:HBIO Harvard Bioscience - HBIO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Harvard Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.96 +0.09 (+3.14%) (As of 01/27/2023 08:55 PM ET) Add Compare Share Share Today's Range$2.83▼$3.0050-Day Range$2.12▼$2.9652-Week Range$1.98▼$6.49Volume47,100 shsAverage Volume79,167 shsMarket Capitalization$123.31 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Harvard Bioscience MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside35.1% Upside$4.00 Price TargetShort InterestHealthy0.72% of Float Sold ShortDividend StrengthN/ASustainability-0.76Upright™ Environmental ScoreNews Sentiment0.08Based on 27 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.03) to $0.13 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.54 out of 5 starsComputer And Technology Sector118th out of 630 stocksAnalytical Instruments Industry5th out of 28 stocks 3.5 Analyst's Opinion Consensus RatingHarvard Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Harvard Bioscience has a forecasted upside of 35.1% from its current price of $2.96.Amount of Analyst CoverageHarvard Bioscience has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.72% of the float of Harvard Bioscience has been sold short.Short Interest Ratio / Days to CoverHarvard Bioscience has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Harvard Bioscience has recently decreased by 32.61%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldHarvard Bioscience does not currently pay a dividend.Dividend GrowthHarvard Bioscience does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHarvard Bioscience has received a 75.20% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Basic medical research services" and "Medical laboratory equipment" products. See details.Environmental SustainabilityThe Environmental Impact score for Harvard Bioscience is -0.76. Previous Next 2.3 News and Social Media Coverage News SentimentHarvard Bioscience has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Computer and Technology companies.News Coverage This WeekMarketBeat has tracked 27 news articles for Harvard Bioscience this week, compared to 12 articles on an average week.Search Interest3 people have searched for HBIO on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Harvard Bioscience insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.20% of the stock of Harvard Bioscience is held by insiders.Percentage Held by Institutions69.37% of the stock of Harvard Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Harvard Bioscience are expected to grow in the coming year, from ($0.03) to $0.13 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harvard Bioscience is -17.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Harvard Bioscience is -17.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHarvard Bioscience has a P/B Ratio of 1.45. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Harvard Bioscience (NASDAQ:HBIO) StockHarvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. It operates under the geographical segments: United States, Germany, United Kingdom, and Rest of the world. It sells its products through catalog, Website, distributors, and direct sales force. The company was founded by Dr. William T. Porter in 1901 and is headquartered in Holliston, MA.Read More Receive HBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harvard Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address HBIO Stock News HeadlinesJanuary 29, 2023 | sportsbookwire.usatoday.comYale at Harvard odds, tips and betting trendsJanuary 28, 2023 | msn.comPenn beats Harvard, 83-68, to climb back to .500January 30, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 28, 2023 | washingtonpost.comHarvard hosts Dingle and PennsylvaniaJanuary 26, 2023 | msn.comAsteroid fly-by Thursday night will be watched by scientists around the world, Harvard astronomer saysJanuary 26, 2023 | msn.comHarvard woman Mary Anderson was fatally shot by ex-boyfriend, authorities concludeJanuary 26, 2023 | msn.comOver 100 Harvard students leave class of professor accused of sexual harassmentJanuary 26, 2023 | nypost.comOver 100 Harvard students walk out of alleged groping professor’s classJanuary 30, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.January 26, 2023 | msn.comHarvard researchers say changing DNA in mice appears to reverse agingJanuary 25, 2023 | msn.comHarvard researchers reverse aging in miceJanuary 25, 2023 | usatoday.comFact check: Harvard course teaches infant sex development, not gender identityJanuary 25, 2023 | nypost.comJennifer Coolidge is going to Harvard — for Hasty Pudding honorJanuary 25, 2023 | msn.comHarvard Students Walkout To Protest Professor John ComaroffJanuary 25, 2023 | msn.comHarvard, among several Mass. towns, finally has their power back on after 24 hours in darkJanuary 25, 2023 | americanbankingnews.comAnalyzing Harvard Bioscience (NASDAQ:HBIO) and Nautilus Biotechnology (NASDAQ:NAUT)January 24, 2023 | msn.comJennifer Coolidge named Harvard’s Hasty Pudding Woman of the YearJanuary 24, 2023 | msn.comJennifer Coolidge to Bend and Snap Her Way Back to Harvard for Woman of the Year PrizeJanuary 24, 2023 | msn.comHarvard professor says he gets thank-you notes from prisoners, some of which are secretly using smartphones to take his free computer-science classJanuary 24, 2023 | technews.tmcnet.comNoted Medical Entrepreneur Kenji Saito, M.D., J.D. Joins Harvard MedTech's Medical Advisory BoardJanuary 24, 2023 | usatoday.com'White Lotus' star Jennifer Coolidge named Harvard's 2023 Hasty Pudding Woman of the YearJanuary 24, 2023 | msn.comHarvard professor says he gets thank-you notes from prisoners secretly using smartphones to take his free computer-science classJanuary 24, 2023 | sportsbookwire.usatoday.comHarvard at Pennsylvania odds, tips and betting trendsJanuary 23, 2023 | msn.comA recession is far from inevitable, says Harvard's Jason FurmanJanuary 23, 2023 | msn.com'You're out of touch, Rishi': UK PM gets slammed for his speech at Harvard Business SchoolJanuary 22, 2023 | msn.comKim Kardashian gives lecture at Harvard Business School, gets ripped onlineJanuary 21, 2023 | usatoday.comHarvard wins 95-89 against CornellSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive HBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harvard Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address HBIO Company Calendar Last Earnings11/08/2022Today1/30/2023Next Earnings (Estimated)3/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Analytical instruments Sub-IndustryLife Sciences Tools & Services SectorComputer and Technology Current SymbolNASDAQ:HBIO CUSIP41690610 CIK1123494 Webwww.harvardbioscience.com Phone(508) 893-8999Fax508-429-5732Employees475Year Founded1901Price Target and Rating Average Stock Price Forecast$4.00 High Stock Price Forecast$5.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+35.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-290,000.00 Net Margins-5.84% Pretax Margin-6.07% Return on Equity4.00% Return on Assets1.99% Debt Debt-to-Equity Ratio0.65 Current Ratio2.43 Quick Ratio1.20 Sales & Book Value Annual Sales$118.90 million Price / Sales1.04 Cash Flow$0.38 per share Price / Cash Flow7.71 Book Value$2.04 per share Price / Book1.45Miscellaneous Outstanding Shares41,660,000Free Float39,075,000Market Cap$123.31 million OptionableOptionable Beta1.63 Social Links Key ExecutivesJames W. GreenChairman, President & Chief Executive OfficerJennifer CoteChief Financial Officer & TreasurerRyan WallaceVice President-Global Sales, Preclinical SystemsJacques CoumansChief Marketing OfficerJohn J. FrySecretary & Chief Legal CounselKey CompetitorsSemantixNASDAQ:STIXVirnetXNYSE:VHCRenalytixNASDAQ:RNLXWiMi Hologram CloudNASDAQ:WIMIUxinNASDAQ:UXINView All CompetitorsInsiders & InstitutionsGreenwood Capital Associates LLCBought 4,717 shares on 1/26/2023Ownership: 0.678%AMH Equity LtdBought 633,124 shares on 1/20/2023Ownership: 5.411%Bank of New York Mellon CorpSold 4,726 shares on 12/8/2022Ownership: 0.392%Balyasny Asset Management LLCBought 21,509 shares on 11/16/2022Ownership: 0.052%Bank of New York Mellon CorpSold 4,726 shares on 11/15/2022Ownership: 0.392%View All Insider TransactionsView All Institutional Transactions HBIO Stock - Frequently Asked Questions Should I buy or sell Harvard Bioscience stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Harvard Bioscience in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" HBIO shares. View HBIO analyst ratings or view top-rated stocks. What is Harvard Bioscience's stock price forecast for 2023? 1 equities research analysts have issued 1-year target prices for Harvard Bioscience's shares. Their HBIO share price forecasts range from $3.00 to $5.00. On average, they expect the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 35.1% from the stock's current price. View analysts price targets for HBIO or view top-rated stocks among Wall Street analysts. How have HBIO shares performed in 2023? Harvard Bioscience's stock was trading at $2.77 at the start of the year. Since then, HBIO stock has increased by 6.9% and is now trading at $2.96. View the best growth stocks for 2023 here. Are investors shorting Harvard Bioscience? Harvard Bioscience saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 265,600 shares, a decrease of 32.6% from the December 31st total of 394,100 shares. Based on an average trading volume of 137,800 shares, the days-to-cover ratio is presently 1.9 days. Currently, 0.7% of the shares of the stock are sold short. View Harvard Bioscience's Short Interest. When is Harvard Bioscience's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023. View our HBIO earnings forecast. How were Harvard Bioscience's earnings last quarter? Harvard Bioscience, Inc. (NASDAQ:HBIO) issued its quarterly earnings data on Tuesday, November, 8th. The medical instruments supplier reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.03 by $0.05. The medical instruments supplier had revenue of $26.92 million for the quarter, compared to analyst estimates of $28 million. Harvard Bioscience had a positive trailing twelve-month return on equity of 4.00% and a negative net margin of 5.84%. What guidance has Harvard Bioscience issued on next quarter's earnings? Harvard Bioscience updated its fourth quarter 2022 earnings guidance on Friday, December, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $30.00 million-$30.00 million, compared to the consensus revenue estimate of $32.78 million. What other stocks do shareholders of Harvard Bioscience own? Based on aggregate information from My MarketBeat watchlists, some companies that other Harvard Bioscience investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), NVIDIA (NVDA), LightPath Technologies (LPTH), Micron Technology (MU), Nokia Oyj (NOK), Evoke Pharma (EVOK), General Electric (GE) and Gilead Sciences (GILD). What is Harvard Bioscience's stock symbol? Harvard Bioscience trades on the NASDAQ under the ticker symbol "HBIO." Who are Harvard Bioscience's major shareholders? Harvard Bioscience's stock is owned by many different retail and institutional investors. Top institutional investors include AMH Equity Ltd (5.41%) and Greenwood Capital Associates LLC (0.68%). Insiders that own company stock include Alan I Edrick, Bertrand Loy, James W Green and James W Green. View institutional ownership trends. How do I buy shares of Harvard Bioscience? Shares of HBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Harvard Bioscience's stock price today? One share of HBIO stock can currently be purchased for approximately $2.96. How much money does Harvard Bioscience make? Harvard Bioscience (NASDAQ:HBIO) has a market capitalization of $123.31 million and generates $118.90 million in revenue each year. The medical instruments supplier earns $-290,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis. How many employees does Harvard Bioscience have? The company employs 475 workers across the globe. Does Harvard Bioscience have any subsidiaries? The following companies are subsidiares of Harvard Bioscience: Data Sciences International.Read More How can I contact Harvard Bioscience? Harvard Bioscience's mailing address is 84 OCTOBER HILL RD, HOLLISTON MA, 01746. The official website for the company is www.harvardbioscience.com. The medical instruments supplier can be reached via phone at (508) 893-8999, via email at info@harvardbioscience.com, or via fax at 508-429-5732. This page (NASDAQ:HBIO) was last updated on 1/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.